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The effect of the prescription opioid crisis in North America is well documented.1 In 2018 
some 68 500 Americans died from opioid overdoses, and in 2015 the cost of opioid misuse to 
the US economy was estimated at $150bn (£110bn; €120bn).1 The EU now has an estimated 
1.3 million high-risk opioid users,1 and 110 000 people worldwide died from opioid use 
disorders in 2017—77% more than in 2007.2 
Opioids were prescribed to roughly 5% of the UK population in 2015.3 Between 1998 and 
2016, opioid prescriptions increased by 34% in England, and the total oral morphine 
equivalence dose increased by 127% to 431 000 mg/1000 population/year.4 A recent UK 
study found that 14.6% of people given opioids for the first time became long term opioid 
users within a year.5 
In response to this healthcare crisis, the UK Medicines and Healthcare Products 
Regulatory Agency (MHRA) has issued recommendations that before prescribing opioids, 
clinicians must discuss the risks and features of tolerance, dependence, and addiction with 
patients, and jointly agree a treatment strategy and plan for the end of treatment.6 These new 
recommendations have the potential to alter opioid prescribing habits substantially. The UK 
General Medical Council advises that clinicians should comply with MHRA 
recommendations along with other guidance, making compliance a professional duty.7 
Appropriate prescribing of opioids should be a priority, focusing where possible on non-
pharmacological strategies, including referral to wellbeing services, physiotherapy, exercise, 
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Clinicians in primary and secondary care will need to work together to ensure that 
patients receive the correct information in an accessible format before starting a course of 
opioids, and that a deprescribing plan is agreed to. All stakeholders will need to recognise 
that opioids are of limited use for chronic pain and that opioids prescribed for non-cancer 
pain must be considered a “course” of treatment with a definite end date. 
Furthermore, the MHRA acknowledges that patients at particular risk will need regular 
monitoring and support.6 This puts the onus on clinicians to ensure that repeat prescriptions 
for opioids are carefully assessed.9 This applies equally to online consultations. Regular 
structured prescription reviews should take place3 and software tools used to identify patients 
with higher risks—such as people taking high dose opioids or who are prescribed concurrent 
medicines such as benzodiazepines. Repeat-refill prescriptions have been identified as one of 
the main drivers for persistent opioid use,10 and have been raised as an area for action to 
prevent future deaths in a recent regulation 28 report.11 Coroners issue regulation 28 reports 
only in exceptional circumstances,12 and this report was published after the death from 
overdose of an old man supplied with 100 tramadol capsules every month on repeat 
prescription with no review.11 
The MHRA also highlights the issues of opioid tolerance, dependence, and addiction and 
recommends slow tapering after prolonged treatment.6 Providing information on the effect of 
opioids on the ability to drive safely can help engage patients in discussions about their 
opioid prescriptions. In addition, interdisciplinary chronic pain rehabilitation programmes 
have been shown to be effective in promoting opioid weaning after long term use.13 However, 
simple deprescribing is unlikely to be successful for patients with an opioid use disorder, who 
often have complex psychological needs. They may benefit from enrolment in opioid agonist 
treatment programmes.14 These will need to be expanded, with implications for resources in 
primary and secondary care. 
The MHRA also reminds clinicians that transdermal fentanyl patches are contraindicated 
in patients who have not previously received opioids6 as they are associated with persistent 
opioid use.10 This advice should be expanded and applied to all modified release opioid 
preparations, including modified release oxycodone, especially in surgical patients.9 
Wider approach 
Although the MHRA recommendations will need to be adhered to within the UK, they 
are equally applicable globally, especially as drug companies are now aggressively marketing 
their products in low and middle income countries.15 An important omission in the 
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recommendations is opioid diversion, which is major cause of harm. Around half of adults 
who misuse opioids obtain them from friends and family.16 Furthermore, mortality in children 
and young people from unintentional opioid overdose continues to rise, with the increase in 
availability of opioids within the community.17 Thus, it is essential that patients understand 
how to store medicines securely and dispose of unused doses safely.9 
A wider and more coordinated approach is necessary to tackle opioid use and misuse. 
Opioid stewardship programmes are needed, which include “coordinated interventions 
designed to improve, monitor, and evaluate the use of opioids to support and protect human 
health.”18 The MHRA recommendations should be regarded as an important advance in 
opioid stewardship. 
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